Skip to main content

Table 1 Baseline characteristics of all obese adolescent girls at study entry

From: Effects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girls

 

RhGH + N = 11

RhGH - N = 11

P

Age (years)

16.2 ± 2.6

16.9 ± 2.2

0.50

Bone age (years)

16.9 ± 1.2

17.2 ± 1.3

0.56

Weight (kg)

104.7 ± 24.8

97.4 ± 15.4

0.42

BMI (kg/m2)

40.4 ± 8.4

36.6 ± 6.4

0.25*

BMI SDS

2.3 ± 0.4

2.1 ± 0.4

0.22

Waist circumference (cm)

119.4 ± 17.1

115.0 ± 14.8

0.53

W/H ratio

0.95 ± 0.06

0.93 ± 0.08

0.62

SAT (cm2)

615.6 ± 175.0

580.0 ± 176.9 (N = 9)

0.66

VAT (cm2)

90.6 ± 35.3

87.1 ± 31.8 (N = 9)

0.82

TAT (cm2)

706.2 ± 203.5

667.2 ± 179.8 (N = 9)

0.66

Thigh subcutaneous fat (cm2)

224.2 ± 69.4

221.4 ± 96.3

0.95

Lean mass (grams)

54353 ± 9719

52276 ± 6842

0.57

IGF-1 (ng/mL)

250.6 ± 129.9

271.8 ± 73.1

0.64

2 HR glucose (OGTT) (mg/dL)

107.1 ± 20.5

114.0 ± 18.5

0.42

HbA1c (%)

5.78 ± 0.30

5.49 ± 0.30

0.03

Insulin uU/mL

26.4 ± 21.3

40.1 ± 37.2

0.29*

Total cholesterol (mg/dL)

167.6 ± 38.3

156.0 ± 33.5

0.46

LDL (mg/dL)

103.8 ± 28.8

92.6 ± 30.1

0.33*

HDL (mg/dL)

45.1 ± 9.4

43.3 ± 8.5

0.64

VLDL (mg/dL)

18.6 ± 9.4

20.1 ± 8.0

0.70

Triglycerides (mg/dL)

93.0 ± 47.0

100.6 ± 39.8

0.69

hsCRP (mg/L)

4.47 ± 2.76

3.41 ± 3.29

0.25*

sICAM-1 (ng/mL)

268.7 ± 72.5

220.9 ± 56.4

0.10

  1. *P value reported for log transformed values.
  2. RhGH+: Group that received rhGH; RhGH-: Group that received placebo/no treatment.
  3. Abbreviations: BMI body mass index, BMI SDS body mass index standard deviation score, HbA1c hemoglobin A1c, HDL high density lipoprotein, hsCRP high sensitivity C-reactive protein, IGF-1 insulin like growth factor-1, LDL low density lipoprotein, OGTT oral glucose tolerance test, SAT subcutaneous adipose tissue, sICAM-1 soluble intercellular adhesion molecule 1, TAT, VAT total, visceral adipose tissue, VLDL very low density lipoprotein, W/H waist to hip ratio.